stockportfolio.pro
Avalyn Pharma Inc. (AVLN)
Healthcare · Biotechnology · NasdaqGS
Avalyn Pharma Inc. revenue & earnings — last 2 fiscal years
| Metric | 2024 | 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | — | — |
| Net income | $-49.74M | $-85.20M |
| Net margin | — | — |
Source: Avalyn Pharma Inc. SEC filings (10-K).
Explore 2 years of Avalyn Pharma Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track AVLN in your portfolio →
Avalyn Pharma Inc. financial history by metric
About Avalyn Pharma Inc.
Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs. Its current pipeline is focused on treating pulmonary fibrosis. Its products include AP01 and AP02, inhaled formulations of pirfenidone and nintedanib for the treatment of progressive pulmonary fibrosis and idiopathic pulmonary fibrosis; and AP03, a fixed-dose combination of inhaled pirfenidone and nintedanib to deliver dual antifibrotic mechanisms. Avalyn Pharma Inc. was formerly known as Genoa Pharmaceuticals, Inc. and changed its name to Avalyn Pharma Inc. in July 2017. The company was incorporated in 2011 and is based in Boston, Massachusetts.
Avalyn Pharma Inc. — frequently asked questions
What is Avalyn Pharma Inc.'s revenue?
Avalyn Pharma Inc. (AVLN) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Avalyn Pharma Inc. profitable?
No — AVLN reported a net loss of $-85.20M in fiscal 2025.
What is AVLN's P/E ratio?
Avalyn Pharma Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Avalyn Pharma Inc. have?
As of fiscal year 2025, AVLN carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Avalyn Pharma Inc.'s market cap?
Avalyn Pharma Inc. (AVLN) has a market capitalization of about $1.27B, based on the latest data in our nightly-refreshed cache.
When does Avalyn Pharma Inc.'s fiscal year end?
AVLN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Avalyn Pharma Inc.'s official SEC filings (10-K and 10-Q), covering 2 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.